Roivant Sciences’ (ROIV) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Roivant Sciences (NASDAQ:ROIV) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $18.00 target price on the stock.

Separately, Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $17.93.

Roivant Sciences Trading Up 0.1 %

Shares of ROIV opened at $10.45 on Tuesday. The stock’s 50-day moving average price is $11.41 and its two-hundred day moving average price is $11.59. Roivant Sciences has a 12 month low of $9.76 and a 12 month high of $13.06. The company has a market capitalization of $7.61 billion, a PE ratio of 1.85 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.65% and a net margin of 3,827.42%. Equities research analysts predict that Roivant Sciences will post -1.19 EPS for the current fiscal year.

Insider Transactions at Roivant Sciences

In related news, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00. Following the transaction, the chief operating officer now owns 732,294 shares in the company, valued at approximately $8,260,276.32. This represents a 12.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the purchase, the director now owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. The trade was a 21.11 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 1,942,629 shares of company stock worth $23,034,486 in the last 90 days. Insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

Institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its stake in Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock valued at $28,000 after purchasing an additional 1,948 shares during the last quarter. Gladius Capital Management LP bought a new stake in Roivant Sciences during the 3rd quarter valued at $35,000. US Bancorp DE raised its holdings in Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after acquiring an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in Roivant Sciences during the 4th quarter valued at $39,000. Finally, GAMMA Investing LLC raised its holdings in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.